Article Text

PDF
THU0482 Evolution of comorbid fibromyalgia frequency in axial spondyloarthritis patients starting an anti-tnf agent, and correlation to anti-tnf efficacy. the predict-spa study
  1. S Perrot,
  2. A Moltό,
  3. A Etcheto,
  4. N Boudersa,
  5. P Claudepierre,
  6. N Roux,
  7. F Berenbaum,
  8. A Martin,
  9. L Sparsa,
  10. P Coquerelle,
  11. M Soubrier,
  12. L Gossec,
  13. M Dougados
  1. Predict-SpA Study Group, Paris, France

Abstract

Background Fibromyalgia (FM) is a frequent comorbid condition in axial spondyloarthritis (axSpA). It is not known how FM comorbidity may respond to the management of SpA, and especially to anti-TNF agents.

Objectives To evaluate the change of comorbid FM status of axSpA patients starting an anti-TNF treatment.

Methods A prospective multicenter national study involving 39 rheumatology centers in France, analyzing 519 patients with axSpA requiring anti-TNF therapy (ClinicalTrials.gov: NCT03039088). Patients were screened for FM with the FiRST questionnaire before and after 3 months of anti-TNF. Kappa coefficient was calculated to determine the agreement of the FiRST at M0 and M3. Response to anti-TNF (BASDAI50 response was compared according to positive screening for FM or not, at both time-points using chi2 tests.

Results Of the 519 enrolled pts, 504 (with complete data on the FiRST questionnaire) were analyzed at M3. A positive screening for comorbid FM was found in 192 pts (38%) at M0 and in 127 (25%) pts at M3. Correlation between FiRST at M0 and M3 was weak with a Kappa coefficient correlation of 0.4 [0,3 - 0,5].

Four groups were identified: group [+/+] with comorbid FM at M0 and M3: N=93 (18%; group [+/-] with comorbid FM at M0 but not at M3: N=99 (20%); group [-/-] without comorbid FM at M0 and M3: N=278 (55%); group [-/+] without comorbid FM at M0 but at M3: N=34 (7%)

Changes in the status of comorbid FM (disappearance or appearance) was observed in 134 pts (26%). In the 193 pts with baseline comorbid FM, after 3 months of anti-TNF treatment, comorbid FM was no longer found in 99 (51%)%.Efficacy at M3 was significantly better, according to BASDAI 50, in patients without comorbid FM at M3 (Table).

Conclusions There is a high frequency of comorbid FM screened by the FiRST in active axSpA, decreased by 51%f after 3 months of anti-TNF treatments. Persistence of FM after 3 months of anti-TNF treatment is associated with lower anti-TNF response. Further studies are required to analyze the impact of screening FM before starting anti-TNF therapy in axSpA.

References

  1. Perrot S, et al. Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain. 2010;150:250–6.

References

Acknowledgements This study was conducted thanks to an unrestricted grant from MSD.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.